Recent News
Radiopharmaceutical May Benefit Patients with Metastatic Prostate Cancer Sooner
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.
NewYork-Presbyterian Hospital Named One of the Nation’s Best Hospitals by U.S. News & World Report For 23rd Year in a Row and a #1 Hospital in New York
U.S. News & World Report recognizes NewYork-Presbyterian Hospital for excellence, with eight specialties ranked in the top five and ten specialties in the top ten, nationally.
NewYork-Presbyterian Adopts Signal 1's AI Management System to Advance Healthcare Innovation and Enhance Patient Safety
NewYork-Presbyterian today announced its adoption of Signal 1's AI Management System (AIMS) and plans to work closely with the technology company to support the safe management and monitoring of artificial intelligence technologies across the institution — from tools that help detect cancer and structural heart disease to applications that support discharge planning and clinical documentation.
Columbia University Orthopedics Announces New Physician Leadership Team for Columbia Athletics
The Columbia University Vagelos College of Physicians and Surgeons (VP&S) Department of Orthopedic Surgery today announced a new physician leadership team for Columbia Athletics.
Tumor Organoid Tech Advances Toward a Sci-Fi Future
Significant advances have been made in the development of patient-derived tumor “organoids” for preclinical research, in two new studies led by Weill Cornell Medicine investigators.
Featured Stories
